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Abstract 
Background: Insulinomas are rare pancreatic endocrine tumors. Most are benign and solitary. However, the nonspe-
cific symptoms and small size of these tumors led to difficulties of diagnosis and localization.
Case presentation: We present two Arab patients with pancreatic long-standing insulinoma. Both patients pre-
sented episodic hypoglycemic symptoms respectively during 10 and 2 years. Biochemical and morphological workup 
detected localized pancreatic insulinoma. Open procedure surgery was done for the two patients and insulinomas 
were successfully removed by enucleation.
Conclusion: Insulinoma remains a diagnostic challenge to practitioners. Diagnosis of suspected cases is easily 
confirmed by standard endocrine tests, especially the supervised fasting test. Accurate preoperative localization is 
essential for more effective and safest surgery.
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Background
Among pancreatic endocrine tumors, insulinoma is the 
most common type. This tumor was reported in 1–4 
people per one million person years [1]. It can be seen 
at any age and occurs slightly more frequently in female 
than male [2]. Usually insulinoma clinical presentation 
is benign, with a solitary and small size (<2 cm in diam-
eter). Most are sporadic, however, 10  % of insulinomas 
are multiple and occur as part of multiple endocrine neo-
plasia syndrome type I (MEN–I). Because of nonspecific 
symptoms, insulinoma may be misdiagnosed with other 
disorders. Patients often present with hypoglycemia signs 
resulting from inappropriate insulin secretion [3]. After 
biochemical confirmation of hyperinsulinism, preopera-
tive localization of the tumor in the pancreas may be dif-
ficult. Surgical removal, often curative, continues to be 
the treatment of choice.
In this manuscript, we report 2 cases of pancreatic 
insulinoma, and we discuss diagnosis, localization and 
management of this uncommon disease.
Case presentation 1
A 60-year-old Arab male had history of episodic and 
repetitive symptoms including diaphoresis, tremors, 
palpitations, and occasional loss of consciousness since 
10 years. These symptoms, associated with a weight gain 
and a chronic weakness, occurred especially at night 
away from meals and were relieved with eating some-
thing. He had no family history of endocrine disease. 
Physical examination showed a healthy man with a Body 
Mass Index (BMI) of 34.9 kg/m2. Blood laboratory tests 
demonstrated a low initial glucose level at 46  mg/dl 
(70–11 mg/dl), a high plasma insulin level at 70.4 μIU/ml 
(2.6–24.9 μIU/ml), and a high C-peptide level at 6.76 ng/
ml (0.8–4.2  ng/ml). Prolonged supervised fasting test 
was applied and produced symptomatic hypoglycemia 
with hyperinsulinemia. Urine for sulfonylurea screen was 
negative. Abdominal computed tomography (CT) scan 
with contrast demonstrated a well-defined hypervascular 
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lesion involving uncinate process of pancreas measuring 
15  mm in diameter with enhancement during the arte-
rial phases of contrast bolus (Fig.  1), but without liver 
metastasis or intra-abdominal lymph nodes. Magnetic 
resonance imaging (MRI) of brain was also performed 
showing an enlarged pituitary gland without nodular 
lesions. Other hormonal studies including serum corti-
sol level, parathormone level, adrenocorticotropic hor-
mone (ACTH) level, and thyroid function were normal. 
Regarding the normal hormonal assessment, multiple 
endocrine neoplasia was eliminated.
Open surgical exploration was made. Complete mobi-
lization and careful bimanual palpation of the pancreas 
allowed identifying a firm and well-circumscribed nod-
ule at the uncinate process. Nodule enucleation was 
performed and pathological examination revealed an 
encapsulated pancreatic mass measuring 15  ×  15  mm. 
Mitotic index was about 4 per 10 high-power fields (HPF) 
and proliferation index ki-67 was estimated at 10  %. 
Immunohistochemically, tumor cells showed a positive 
and diffuse staining for synaptophysin. Complemen-
tary staining for insulin was not preformed because not 
available in our institution. Therefore, an intermediate 
grade neuroendocrine tumor of pancreas was identified. 
Regarding to functional status and biological behav-
ior, diagnosis of pancreatic insulinoma was confirmed. 
Immediately after surgical treatment, the glucose level 
increased to the normal range. The patient was discharged 
without any hypoglycemic symptoms after 4  days. The 
patient remains asymptomatic within 6 months follow up.
Case presentation 2
A 47-year-old Arab female suffered from hypogly-
cemic attacks characterized by dizziness, fatigue, 
tremulousness, sweating, and hunger, associated with 
weight gain for 2  years. Most episodes occurred in the 
evening with a worsening of symptoms during pro-
longed fasting of Ramadan. She had no family history 
of endocrine disease. Physical examination showed a 
well-nourished patient with a BMI of 52.5 kg/m2. Blood 
laboratory tests revealed, a low glucose level at 39 mg/dl 
(70–11  mg/dl); a high plasma insulin level at 65.2 μIU/
ml (2.6–24.9 μIU/ml), and a C-peptide level at 4.99 ng/
ml (0.8–4.2 ng/ml). Prolonged supervised fasting test was 
applied and produced symptomatic hypoglycemia with 
hyperinsulinemia. Urine for sulfonylurea screen was neg-
ative. Abdominal CT scan with contrast demonstrated a 
hypervascular lesion involving head of pancreas measur-
ing 20  ×  17  mm with enhancement during the arterial 
phases of contrast bolus, but without liver metastasis or 
intra-abdominal lymph nodes. Abdominal MRI showed a 
nodule located at the junction head uncinate process of 
pancreas with intimate relationship to the second por-
tion of duodenum but without bile or pancreatic ducts 
dilatation (Fig.  2). Thus, endoscopic ultrasonography 
(EUS) was performed showing a rounded hypoechoic 
mass of pancreatic head. MRI of hypophysis and cervical 
Fig. 1 Axial computed tomography scan image: mass in the 
uncinate process of pancreas measuring 15 mm in diameter with 
bright contrast enhancement during arterial phase (arrow), without 
pathologic intra- abdominal lymph nodes
Fig. 2 Abdominal magnetic resonance imaging findings: pancreatic 
nodule with low signal intensity on T1-weighted images (lesion arrow) 
(a) and high signal intensity on T2-weighted images (nodule arrow) 
(b)
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ultrasound were normal. Other hormonal studies includ-
ing serum cortisol level, parathormone level, ACTH level 
and thyroid function were normal eliminating a multiple 
endocrine neoplasia.
Open surgical exploration was made. Complete mobi-
lization and careful bimanual palpation of the pancreas 
discovered a firm and unifocal nodule in the pancreatic 
head without relationship to the bile duct. Nodule enu-
cleation was achieved (Fig. 3) and pathological evaluation 
has revealed an encapsulated pancreatic mass measur-
ing 20 × 15 mm (Fig. 4). Mitotic index was about 2 per 
10 HPF and proliferation index ki-67 was estimated at 
10  %. Immunohistochemically, tumor cells showed a 
positive and diffuse staining for synaptophysin (Fig.  5). 
Complementary staining for insulin was not preformed 
because not available in our institution. Finally, an inter-
mediate grade neuroendocrine tumor of pancreas was 
identified. Regarding to functional status and biological 
behavior, diagnosis of pancreatic insulinoma was con-
firmed. Immediately after surgical treatment, the glu-
cose level increased to the normal range. The patient was 
discharged without any hypoglycemic symptoms after 
5 days. The patient is currently in 1 year follow-up with a 
good evolution.
Discussion
Sporadic distribution, small size and high benignity rate 
are known insulinoma features, however etiopatho-
genesis remains still unclear. This rare tumor may have 
variable and nonspecific presentations all referable to 
the hypoglycemic state. Hypoglycemic symptoms can 
be divided into neuroglycopenic signs, most common, 
including confusion, behavioral changes, visual dis-
turbances, weakness, dizziness, seizures and loss of 
consciousness, and neurogenic signs, such as anxiety, 
sweating, palpitations, tremors and feeling of warmth [4, 
5].These symptoms become typically evident after fasting 
and are often precipitated by physical exercises. How-
ever, the median duration of symptoms before diagnosis 
remains variable and can reach 12–18 months on average 
or even years in rare cases [2]. In our report, insulinoma 
diagnosis was delayed for several years. Simply because 
symptoms of hypoglycemia have been misinterpreted 
and misattributed to cardiac and neurological disorders 
before the insulinoma was recognized. In addition, our 
two patients tried to avoid hypoglycemic signs by eating 
frequently with resultant weight gain.
Fig. 3 Operative view showing a nodule in the pancreatic head with 
intimate relationship to the second portion of duodenum (arrow)
Fig. 4 Resected specimen
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Insulinoma is still suggested by the Whipple’s triad 
including: symptoms of hypoglycemia induced by fasting 
or exercise, plasma glucose level below than 45 mg/dl and 
relief of symptoms following the administration of glu-
cose. The supervised 72-h fasting test remains to be the 
gold standard for biochemical diagnosis with measure-
ment of plasma glucose, insulin, C-peptide, and proinsu-
lin during the onset of hypoglycemic symptoms. We used 
this test in our two cases to diagnose hyperinsulinism.
Various preoperative procedures can be used to localize 
the tumor in order to plan therapeutic strategy. The choice 
of procedure depends upon which tests are available and 
local radiologic skills. In our context, multiple noninvasive 
and invasive options are used including trans-abdominal 
ultrasonography, CT scan, MRI and EUS. The reported 
sensitivity of conventional CT and MRI for detection of 
pancreatic insulinoma ranges respectively from 33 to 64 
and 40 to 90  %. However, the advent of helical CT scan 
has enabled detection of about 94 % of insulinomas [1, 4]. 
Consequently, it is currently accepted that CT scan is the 
first-line and MRI is the second-line investigation. These 
modalities can identify the exact size and location of an 
insulinoma, describe its anatomic relationship to sur-
rounding structures and detect the presence of metastatic 
lesions suggestive of malignancy [6].
Some authors consider EUS as the best exam for pre-
operative localization of insulinoma, with a sensitivity of 
up to 94 %. It can detect even small tumors of 5 mm, and 
reveal important relation to the bile duct and adjacent 
blood vessels. Also, EUS allows performing fine-needle 
aspiration cytology of suspicious lesions and preoperative 
marking of tumors to facilitate surgical excision particu-
larly with laparoscopic approach. However, EUS find-
ings depend largely on the examiner’s experience [1, 2]. 
In our institution, we generally use this technique when 
the tumor is not detected with the previously mentioned 
imaging modalities.
Bimanual palpation combined with intraoperative 
ultrasonography (IOUS) is the most effective method 
to detect more than 95  % of tumors, but requires com-
plete mobilization of the pancreas [7, 8]. Because of this 
operative success particularly in the hands of experienced 
surgeons, some authors suggest that preoperative locali-
zation studies are not necessary [9, 10]. However, with 
recent advances in imaging techniques, preoperative 
topographic assessment is considered useful in avoid-
ing blind resection and planning for rapid, accurate and 
safe surgery. Additionally, there is absolutely no question 
that positive localization is required prior to re-operative 
insulinoma [4].
Most insulinomas can be cured with surgery. Surgical 
procedure choice depends on the size and location of 
the mass. Tumor enucleation is the procedure of choice 
especially in case of small and solitary nodule that is not 
encroaching on the pancreatic or bile ducts [11]. The 
lesions are typically reddish-brown, firm, and encapsu-
lated with a clear plane of dissection between the tumor 
and surrounding soft pancreatic parenchyma [12]. In 
addition, recent guidelines suggest that enucleation is 
enough in front of a well-circumscribed lesion, clearly 
localized before surgery, near or at the pancreatic sur-
face, and easily defined intra-operatively [4]. Moreover, 
pancreatic resection is indicated for lesions invading or 
in close proximity to the pancreatic duct or major ves-
sels, or suspicious for malignancy with a hard, infiltrating 
tumor and puckering of the surrounding soft tissue, pan-
creatic duct dilatation or lymph node involvement [4, 13]. 
Resection options include distal pancreatectomy (with or 
without splenectomy), Whipple procedure (pancreati-
coduodenectomy), or median pancreatectomy, depend-
ing on the site of insulinoma.
If the tumor is not identified despite a careful surgical 
exploration with bimanual palpation and IOUS, termi-
nation of the surgical procedure without blind resection 
Fig. 5 Microscopic findings. a Tumor proliferation with endocrine differentiation (hematoxylin-eosin staining, original magnification ×40). b Strong 
and diffuse expression of synaptophysin (immunohistochemistry, original magnification ×100)
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is recommended. In such cases, the patient should be 
evaluated and re-operated at a referral center. Blind dis-
tal pancreatectomy is currently not appropriate and 
must be avoided [10, 14]. Consequently, more extensive 
localization procedures must be applied before reopera-
tion, often including the intra-arterial calcium stimula-
tion test with hepatic venous sampling (IACS-test). This 
test helps to regionalize the lesion preoperatively with a 
high detection rate ranging from 94 to 100 %. [15]. There-
fore, the use of IACS-test allows for a more accurate 
surgical approach and can minimize the likelihood of re-
operation. It may be appropriate when an insulinoma is 
strongly suspected but all previously described tests are 
negative. However, high cost and exclusive availability 
in some specialized centers lead to reserve this modality 
for patients with persistent or recurrent hyperinsulinism 
after initial surgery [16].
Furthermore, laparoscopic approach is currently feasi-
ble and becomes increasingly reported with good results 
in selected patients [17, 18]. Tumor location should be 
confirmed intra-operatively by laparoscopic ultrasonog-
raphy [19, 20]. Both of our patients underwent tumor 
enucleation using open surgical approach. The lesions 
were easily identified thanks to only bimanual palpation 
of the pancreatic parenchyma.
Histologically, insulinomas are epithelial neoplasms 
associated with strong and diffuse immunohistochemi-
cal expression of neuroendocrine markers such as syn-
aptophysin and chromogranin. Mitotic rate (number 
of mitoses per 10 HPF) and proliferation index (Ki-67 
labeling index) are particularly helpful to separate well-
differentiated from poorly differentiated tumors [21]. 
Conversely, Malignant insulinomas are difficult to dis-
tinguish histologically and often the diagnosis of malig-
nancy is only made when metastases occur [10].
Medical management of insulinoma, used to treat and 
prevent hypoglycemia, is generally restricted to unre-
sectable metastatic tumors, unsuccessful operation with 
persistent symptoms, inoperable patients, and patients 
awaiting or refusing surgery [1, 4]. Moreover, other 
recent techniques for the management of insulinoma 
have been reported, including injection of octreotide, 
EUS guided alcohol ablation, radiofrequency ablation, or 
embolization of an insulinoma [1].
Conclusion
Insulinoma is a rare neuroendocrine tumor, usually 
benign, but can be life-threatening in causing hypo-
glycemic accidents. Biochemical diagnosis is easy, but 
preoperative localization may prove difficult. However, 
most insulinomas can be identified intraoperatively by 
experienced surgeons. Surgical resection remains the 
treatment of choice with an extremely high success rate. 
Laparoscopic approach is increasingly performed and 
blind pancreatic resection is not recommended. Finally, 
medical options are reserved for unresectable or meta-
static tumors.
Consent
Written informed consent was obtained from both 
patients for publication of this Case Report and any 
accompanying images. A copy of the written consent is 
available for review by the Editor-in-Chief of this journal.
Abbreviations
MEN-I: multiple endocrine neoplasia syndrome type I; BMI: Body Mass Index; 
ACTH: adrenocorticotropic hormone; CT: computed tomography; MRI: mag-
netic resonance imaging; EUS: endoscopic ultrasonography; HPF: high-power 
fields; IOUS: intraoperative ultrasonography; IACS-test: intra-arterial calcium 
stimulation test with hepatic venous sampling.
Authors’ contributions
MT participated in the conception and design of the report and wrote the 
paper. MBR, MSB, MES, MA, MB, MEL and MO have made substantial contribu-
tions to acquisition, analysis and interpretation of patient’s data. AAA and YS 
have been involved in coordination and design of the report and revision of 
the manuscript. KS participated in drafting and revision of the manuscript. All 
authors read and approved the final manuscript.
Author details
1 Department of Digestive Surgery, Faculty of Medicine and Pharmacy, 
Mohammed V Military Hospital, Mohammed V University, Rabat, Morocco. 
2 Department of Oncology, Faculty of Medicine and Pharmacy, Mohammed 
V Military Hospital, Mohammed V University, Rabat, Morocco. 3 Department 
of Pathology, Faculty of Medicine and Pharmacy, Mohammed V Military Hospi-
tal, Mohammed V University, Rabat, Morocco. 
Acknowledgements
The authors would like to thank the team of Department of Digestive Surgery 
for providing support and helping in preparing this manuscript. Neither 
author received any source of funding for this manuscript.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 3 April 2015   Accepted: 7 September 2015
References
 1. Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, et al. 
Diagnosis and management of insulinoma. World J Gastroenterol. 
2013;19:829–37.
 2. Bouslama K, Maghrebi H, Bedioui H, Bouslama K. Pancreatic insulinoma: 
diagnostic approach and therapeutic modalities. J Afr Hépatol Gastroen-
térol. 2014;8:11–5.
 3. Patel S, Narwari M, Parekh D, Shah V. Insulinoma: case report and 
review of diagnostic and treatment modalities. J Assoc Physicians India. 
2013;61:423–6.
 4. Abboud B, Boujaoude J. Occult sporadic insulinoma: localization and 
surgical strategy. World J Gastroenterol. 2008;14:657–65.
 5. Cryer PE. Symptoms of hypoglycemia, thresholds for their occurrence, 
and hypoglycemia unawareness. Endocrinol Metab Clin North Am. 
1999;28:495–500, v–vi.
Page 6 of 6Tarchouli et al. BMC Res Notes  (2015) 8:444 
 6. McAuley G, Delaney H, Colville J, Lyburn I, Worsley D, Govender P, et al. 
Multimodality preoperative imaging of pancreatic insulinomas. Clin 
Radiol. 2005;60:1039–50.
 7. Correnti S, Liverani A, Antonini G, Paganelli MT, Mercati U. Intraoperative 
ultrasonography for pancreatic insulinomas. Hepatogastroenterology. 
1996;43:207–11.
 8. Norton JA. Intraoperative methods to stage and localize pancreatic and 
duodenal tumors. Ann Oncol. 1999;10(Suppl 4):182–4.
 9. Hashimoto LA, Walsh RM. Preoperative localization of insulinomas is not 
necessary. J Am Coll Surg. 1999;189:368–73.
 10. Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization 
and management. Future Oncol. 2010;6:229–37.
 11. Finlayson E, Clark OH. Surgical treatment of insulinomas. Surg Clin North 
Am. 2004;84:775–85.
 12. Vanderveen K, Grant C. Insulinoma. Cancer Treat Res. 2010;153:235–52.
 13. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol. 2005;19:783–98.
 14. Hirshberg B, Libutti SK, Alexander HR, Bartlett DL, Cochran C, Livi A, et al. 
Blind distal pancreatectomy for occult insulinoma, an inadvisable proce-
dure. J Am Coll Surg. 2002;194:761–4.
 15. Morita S, Machida H, Kuwatsuru R, Saito N, Suzuki K, Iihara M, et al. Pre-
operative localization of pancreatic insulinoma by super selective arterial 
stimulation with venous sampling. Abdom Imaging. 2007;32:126–8.
 16. Tseng LM, Chen JY, Won JG, Tseng HS, Yang AH, Wang SE, et al. The role 
of intra-arterial calcium stimulation test with hepatic venous sampling 
(IACS) in the management of occult insulinomas. Ann Surg Oncol. 
2007;14:2121–7.
 17. Isla A, Arbuckle JD, Kekis PB, Lim A, Jackson JE, Todd JF, et al. Laparoscopic 
management of insulinomas. Br J Surg. 2009;96:185–90.
 18. Jaroszewski DE, Schlinkert RT, Thompson GB, Schlinkert DK. Laparoscopic 
localization and resection of insulinomas. Arch Surg. 2004;139:270–4.
 19. Iihara M, Kanbe M, Okamoto T, Ito Y, Obara T. Laparoscopic ultrasonogra-
phy for resection of insulinomas. Surgery. 2001;130:1086–91.
 20. Lo CY, Lo CM, Fan ST. Role of laparoscopic ultrasonography in intraopera-
tive localization of pancreatic insulinoma. Surg Endosc. 2000;14:1131–5.
 21. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic clas-
sification of neuroendocrine tumors: a review of nomenclature, grading, 
and staging systems. Pancreas. 2010;39:707–12.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
